Nanobiotix (NBTX) Expected to Announce Quarterly Earnings on Wednesday

Nanobiotix (NASDAQ:NBTX) is projected to release its H2 2025 results before the market opens on Wednesday, April 1st. Analysts expect Nanobiotix to post earnings of $0.2012 per share and revenue of $41.9520 million for the quarter. Individuals are encouraged to explore the company’s upcoming H2 2025 earning overview page for the latest details on the call scheduled for Thursday, April 2, 2026 at 11:40 AM ET.

Nanobiotix Price Performance

Shares of NASDAQ:NBTX opened at $29.27 on Wednesday. The firm has a fifty day simple moving average of $26.67 and a two-hundred day simple moving average of $22.37. Nanobiotix has a 52 week low of $2.99 and a 52 week high of $41.89.

Institutional Trading of Nanobiotix

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NBTX. Royal Bank of Canada boosted its position in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Marshall Wace LLP purchased a new stake in shares of Nanobiotix in the fourth quarter worth approximately $220,000. Finally, Millennium Management LLC purchased a new stake in shares of Nanobiotix in the fourth quarter worth approximately $390,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on NBTX shares. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Finally, Guggenheim boosted their target price on Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.